RELMADA THERAPEUTICS, INC. (RLMD) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
RLMD currently has 105M outstanding shares. with moderate dilution risk from 35.2M authorized shares representing 33.5% potential dilution. The company has significantly diluted shareholders by 173.94% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| May 12, 2026 |
10-Q filing | 104.9M shares outstanding |
100M | 35M |
| Apr 03, 2026 |
S-3 filing: This prospectus relates to the resale of up to 33,685,096 shares of Relmada Therapeutics, Inc. common stock by the selling stockholders. |
100M | 35M |
| Mar 19, 2026 |
10-K filing | 104.9M shares outstanding |
100M | 1.5M |
| Mar 09, 2026 |
8-K filing: Relmada Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement with institutional and accredited investors to sell shares of common stock and pre-funded warrants for approximately $160.0 million. ($160.0M proceeds) |
73M | 33M |
| Nov 13, 2025 |
10-Q filing | 73.3M shares outstanding |
73M | 33M |
| Aug 07, 2025 |
10-Q filing | 33.2M shares outstanding |
33M | 73M |
| May 12, 2025 |
10-Q filing | 30.4M shares outstanding |
30M | 76M |
| Mar 27, 2025 |
10-K filing | 30.2M shares outstanding |
30M | 76M |
| Mar 26, 2025 |
8-K filing: Relmada Therapeutics, Inc. entered into an Exclusive License Agreement with Trigone Pharma, Ltd., issuing 3,017,420 restricted shares of Relmada's common stock to Trigone as part of the agreement. |
30M | 76M |
| Nov 07, 2024 |
10-Q filing | 30.2M shares outstanding |
30M | 76M |
| Aug 30, 2024 |
S-3 filing: Relmada Therapeutics, Inc. is offering common stock, preferred stock, warrants, subscription rights, depositary shares, purchase contracts and units for an aggregate initial offering price of up to $250,000,000. |
30M | 76M |
| Aug 07, 2024 |
10-Q filing | 30.2M shares outstanding |
30M | 0 |
| May 08, 2024 |
10-Q filing | 30.1M shares outstanding |
30M | 0 |
| Mar 19, 2024 |
10-K filing | 30.1M shares outstanding |
30M | 0 |
| Nov 08, 2023 |
10-Q filing | 30.1M shares outstanding |
30M | 0 |
| Aug 08, 2023 |
10-Q filing | 30.1M shares outstanding |
30M | 0 |
| May 11, 2023 |
10-Q filing | 30.1M shares outstanding |
30M | 0 |
| Mar 23, 2023 |
10-K filing | 29.6M shares outstanding |
30M | 0 |
| Nov 10, 2022 |
10-Q filing | 30.1M shares outstanding |
30M | 0 |
| Aug 11, 2022 |
10-Q filing | 29.9M shares outstanding |
30M | 0 |
| May 05, 2022 |
10-Q filing | 28.4M shares outstanding |
28M | 0 |
| Mar 25, 2022 |
10-K filing | 29.4M shares outstanding |
29M | 0 |
| Dec 13, 2021 |
8-K filing: Relmada Therapeutics, Inc. closed an underwritten public offering of 8,823,530 shares of common stock at $17.00 per share, and an additional 1,323,529 shares were sold after the Underwriters exercised their option in full on December 9, 2021, for net proceeds of approximately $161.6 million. ($161.6M proceeds) |
18M | 0 |
| Nov 12, 2021 |
10-Q filing | 17.5M shares outstanding |
18M | 0 |
| Aug 10, 2021 |
10-Q filing | 17.5M shares outstanding |
17M | 0 |
| May 12, 2021 |
10-Q filing | 16.8M shares outstanding |
17M | 0 |
| Mar 24, 2021 |
10-K filing | 16.7M shares outstanding |
17M | 0 |
| Nov 12, 2020 |
10-Q filing | 16.2M shares outstanding |
16M | 0 |
| Aug 12, 2020 |
10-Q filing | 16.0M shares outstanding |
16M | 0 |
| Aug 12, 2020 |
S-3 filing: Relmada Therapeutics, Inc. is filing an S-3 form to register an indeterminate aggregate principal amount and number of common stock, preferred stock, subscription rights, depositary shares, purchase contracts, and/or units up to a proposed aggregate offering price of $250,000,000. |
14M | 0 |
| May 15, 2020 |
10-Q filing | 14.5M shares outstanding |
14M | 0 |